First results of the Phase II TITAN trial: anti-von Willebrand ... - Ablynx
First results of the Phase II TITAN trial: anti-von Willebrand ... - Ablynx
First results of the Phase II TITAN trial: anti-von Willebrand ... - Ablynx
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Anti-VWF Nanobody (ALX-0081/ALX-0681)<br />
• Bivalent 28 kD Nanobody<br />
– new mode <strong>of</strong> action<br />
– stops platelet adhesion to vessel wall at<br />
high blood flow<br />
• Positive preclinical data<br />
– potent inhibition <strong>of</strong> clotting without<br />
increasing bleeding potential<br />
– in vitro inhibition <strong>of</strong> platelet adhesion to<br />
ULVWF and <strong>of</strong> platelet string formation<br />
• Potential clinical benefits<br />
– improved efficacy and safety as adjunct<br />
to plasma exchange<br />
Camelidae family has both forms<br />
C H2<br />
C H3<br />
CH1 CL Conventional<br />
<strong>anti</strong>body<br />
Bivalent<br />
<strong>anti</strong>-VWF<br />
Nanobody<br />
V H<br />
V L<br />
C H2<br />
C H3<br />
V HH<br />
Heavy-chain<br />
<strong>anti</strong>body<br />
V HH<br />
<strong>Ablynx</strong>’s<br />
Nanobody<br />
Anti-VWF<br />
Nanobody<br />
Structure : courtesy <strong>of</strong> Steyaert et al, VUB<br />
12
Change language